P/E ratio for Adicet Bio (ACET)
P/E ratio as of January 2023 (TTM): -6.33
According to Adicet Bio's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.33333. At the end of 2021 the company had a P/E ratio of -8.45.
P/E ratio history for Adicet Bio from 2020 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -8.45 | 138.18% |
| 2020 | -3.55 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 9.14 | -244.33% | 🇨🇭 Switzerland |
 Pfizer PFE | 8.17 | -229.05% | 🇺🇸 USA |
 Merck MRK | 17.6 | -378.32% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -9.11 | 43.86% | 🇮🇱 Israel |
 Hawkins HWKN | 13.9 | -319.70% | 🇺🇸 USA |
 Quaker Houghton KWR | 44.8 | -807.63% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.